GP
LKFT

GLG Partners’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

GLG Partners’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$279K Buy
+2,979
New +$282K 0.01% 366
2016
Q1 		– Sell
-70,309
Closed -$4.42M – 445
2015
Q4 		$4.42M Buy
70,309
+58,625
+502% +$3M 0.14% 168
2015
Q3 		$476K Buy
11,684
+465
+4% +$26.8K 0.01% 404
2015
Q2 		$578K Buy
+11,219
New +$595K 0.02% 395

Other funds holding LKFT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

GLG Partners's LKFT Position: Q4 2017 in Review

GLG Partners opened a new position in Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q4 2017: 2,979 shares worth $279K. The stake represents 0.01% of the portfolio and ranks #366 among its holdings. This is a return to the name: GLG Partners previously reported a position in LKFT as recently as Q4 2015.

GLG Partners first reported a position in LKFT in Q2 2015 and has held it in 4 quarters since. The position peaked at $4.42M in Q4 2015. 77 funds tracked by Wall St. Rank hold LKFT as of Q4 2017.

  • GLG Partners held 2,979 shares of Lakefront Biotherapeutics American Depositary Shares worth $279K as of Q4 2017.
  • Lakefront Biotherapeutics American Depositary Shares was a new GLG Partners position in Q4 2017.
  • Lakefront Biotherapeutics American Depositary Shares made up 0.01% of GLG Partners's portfolio in Q4 2017, its #366 holding.
  • GLG Partners first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q2 2015 and has held it in 4 quarters since.
  • GLG Partners's Lakefront Biotherapeutics American Depositary Shares position peaked at $4.42M in Q4 2015.
  • 77 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q4 2017.

Based on GLG Partners's 13F filing for Q4 2017, filed 14 Feb 2018.